Wells Fargo Upgrades VRDN to 'Buy' with $31 Price Target
Wells Fargo has upgraded VRDN's rating to 'Buy', setting a price target of $31, a 64.98% upside from the current price.
Key Points
- Wells Fargo upgraded VRDN to 'Buy' with a new price target of $31, announced on June 29, 2026.
- Wells Fargo's $31 price target implies 64.98% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.79 share price.
- VRDN shares traded near $17.90 on Monday, with notable institutional interest from funds like BlackRock and FMR LLC.
- Insider transactions include buys by Fairmount Funds Management and sales by several top executives.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wells Fargo analyst Derek Archila has raised the rating on VRDN to 'Buy' and set a price target of $31. This upgrade was announced on June 29, 2026, reflecting increased confidence in VRDN's potential.
Wells Fargo vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in VRDN
FMR LLC grew its holdings by 994,921 shares, ending with 15,379,377 shares worth about $300.8 million, a 6.9% increase. BlackRock, Inc. added 1,399,552 shares, bringing its total to 7,831,475 shares valued at approximately $153.2 million, marking a 21.8% increase. Bellevue Group AG also increased its stake by 2,367,617 shares, now holding 6,726,144 shares worth $131.6 million, a 54.3% boost. State Street Corp added 1,206,325 shares, reaching 4,672,885 shares valued at $91.4 million, a 34.8% increase. Vanguard Capital Management LLC opened a new position with 4,167,201 shares valued at $81.5 million.
Viridian Therapeutics, Inc. Stock Down 18.6%
Shares of VRDN traded near $17.90 on Monday. The stock has attracted considerable interest from institutional investors, as seen in the recent activity by major funds.
$VRDN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Viridian Therapeutics, Inc.
Fairmount Funds Management LLC purchased 1,176,470 shares on May 11, 2026, at an average price of $17.00. Meanwhile, several top executives, including Chief Legal Officer Jennifer Tousignant and CEO Stephen Mahoney, sold shares on March 3, 2026, at an average price of $30.19. Tousignant also bought 5,169 shares on the same day.
Analysts Set New Price Targets
On June 29, 2026, Wells Fargo upgraded VRDN to 'Buy' with a $31 price target. Evercore ISI Group maintained its 'Buy' rating with a $26 target on May 15, 2026. RBC Capital reiterated its 'Buy' stance with a $34 target on May 6, 2026. Truist Securities also maintained a 'Buy' rating, setting a $33 target on April 21, 2026.
Bottom Line
Wells Fargo's upgrade to 'Buy' and the new $31 price target highlights growing optimism about VRDN. Institutional activity and insider trades show active interest in the stock. Remember, analyst ratings are forward-looking opinions and may influence investor sentiment, but they are not guarantees of future performance.
Get Viridian Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.